Infection and chemotherapy

The Korean Society of Infectious Diseases (대한감염학회)
권호 표지
DOI QR코드

DOI QR Code

Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years

  • Received : 2018.06.21
  • Accepted : 2018.09.23
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Backgroud: Influenza vaccination is recommended for adults aged ${\geq}65$ years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which is marketed as $FLUAD^{(R)}$ and $VANTAFLU^{(R)}$, in South Korean subjects aged ${\geq}65$ years. Materials and Methods: Solicited local and systemic adverse events (AEs) were collected from day 1 to 4 of the study. All unsolicited AEs and serious AEs (SAEs) were recorded from day 1 until study termination (day 29). Results: Of the 770 subjects enrolled ($FLUAD^{(R)}$, n = 389; $VANTAFLU^{(R)}$, n = 381), 39% overall experienced any solicited AE. Local AEs were reported by 33% of subjects overall; with the most common events being injection-site pain (30%) and tenderness (27%). Systemic AEs were reported by 19% of subjects overall with the most common events being myalgia (11%) and fatigue (8%). Conclusion: These results show that the MF59-adjuvanted influenza vaccine known as $FLUAD^{(R)}$ or $VANTAFLU^{(R)}$ had acceptable safety profiles in older adults (aged ${\geq}65$ years) in South Korea.

Keywords

References

  1. World Health Organization (WHO). Influenza (Seasonal). Fact sheet 211. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 5 December, 2016.
  2. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005;23 (Suppl 1):S10-25. https://doi.org/10.1016/j.vaccine.2005.04.019
  3. McElhaney JE. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health 2008;4:603-13. https://doi.org/10.2217/1745509X.4.6.603
  4. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montano LF, Nichol KL, Puig-Barbera J, Schmitt J, Stephenson I. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009;27:5043-53. https://doi.org/10.1016/j.vaccine.2009.06.032
  5. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect 2014;68:363-71. https://doi.org/10.1016/j.jinf.2013.11.013
  6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86. https://doi.org/10.1001/jama.289.2.179
  7. Tsai TF. Fluad(R)-MF59(R)-adjuvanted influenza vaccine in older adults. Infect Chemother 2013;45:159-74. https://doi.org/10.3947/ic.2013.45.2.159
  8. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines 2012;11:985-94. https://doi.org/10.1586/erv.12.61
  9. Loubet P, Loulergue P, Galtier F, Launay O. Seasonal influenza vaccination of high-risk adults. Expert Rev Vaccines 2016;15:1507-18. https://doi.org/10.1080/14760584.2016.1188696
  10. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-81. https://doi.org/10.1056/NEJMoa070844
  11. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002;2:659-66. https://doi.org/10.1016/S1473-3099(02)00437-1
  12. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007;211:144-56. https://doi.org/10.1002/path.2104
  13. McElhaney JE, Coler RN, Baldwin SL. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 2013;12:759-66. https://doi.org/10.1586/14760584.2013.811193
  14. Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, Shay DK, Belongia EA, Griffin MR. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012;30:3937-43. https://doi.org/10.1016/j.vaccine.2012.03.071
  15. US Food and Drug Administration (FDA). FDA approves first seasonal influenza vaccine containing an adjuvant. November 24, 2015. FDA. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm474295.htm, Accessed 5 December, 2016.
  16. $FLUAD^{(R)}$ - Seqirus Inc. US Package Insert. 2017. Available at: https://www.fluad.com/Common/docs/FLUAD_Package_Insert.pdf. Accessed 17 December 2018.
  17. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-65. https://doi.org/10.1016/j.vaccine.2009.08.101
  18. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80. https://doi.org/10.1016/S0264-410X(00)00499-0
  19. Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an $MF59^{(R)}$-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014;32:5027-34. https://doi.org/10.1016/j.vaccine.2014.07.013
  20. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003;49:177-84. https://doi.org/10.1159/000069172
  21. Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 2004;23:283-9. https://doi.org/10.1016/j.vaccine.2004.07.017
  22. Korean Food and Drug Administration (KFDA). Standard for re-examination of new drugs, etc. Notice 2010-94. KFDA. Available at: http://www.mfds.go.kr. Accessed 8 December, 2016. Available at: http://www.mfds.go.kr/eng/eng/download.do;jsessionid=Qdf0OVydKyvDW7rj3gnAaUolis1V0LVatvGaznJkykFKbEyUQlIRqNKOjLZeg78L?boardCode=17840&boardSeq=70880&fileSeq=1.
  23. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17:3094-101. https://doi.org/10.1016/S0264-410X(99)00138-3
  24. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104. https://doi.org/10.1016/S0264-410X(98)00185-6
  25. Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA; PHAC /CIHR Influenza Research Network. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccin Immunother 2013;9:2460-73. https://doi.org/10.4161/hv.25580
  26. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003;348:1322-32. https://doi.org/10.1056/NEJMoa025028
  27. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40. https://doi.org/10.1001/jama.292.11.1333
  28. Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ. The Korean influenza national immunization program: history and present status. Infect Chemother 2017;49:247-54. https://doi.org/10.3947/ic.2017.49.4.247

Cited by

  1. An Introduction of the Active Vaccine Safety Surveillance System in Foreign Countries vol.44, pp.4, 2019, https://doi.org/10.21032/jhis.2019.44.4.317
  2. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients vol.16, pp.6, 2018, https://doi.org/10.1080/21645515.2019.1692559